Table 4.
Overview of clinical efficacy of NS5A inhibitors
| NS5A-Inhibitor | Company | Phase | Number of patients | Dose per day | Duration | Viral response | Side effects | Active against genotype |
|---|---|---|---|---|---|---|---|---|
| Daclatasvir (DCV) BMS-79005247–49 | BMS | II | 395 (G1 365, G4 30) COMMAND-1 |
20–60 mg QD | NS5A.I + PR 12–24 w + PR 12–36 w (max 48 w) | Naïve GT1: SVR12: 64% (G1a: 58%, G1b: 78–87%) GT4: SVR12: 100% |
Nausea and dry skin | 1,4 |
| 419 COMMAND-2 |
20–60 mg QD | NS5AI + PR 24 w | Null-R: cEVR: 30–34% Partial R: cEVR: 44–57% |
1 | ||||
| 151 COMMAND-GT2/3 |
60 mg QD | NS5A.I + PR 12 w ± PR 12 w RGT NS5A.I + PR 16 w ± PR 12 w RGT versus PR 24 w |
Naïve G2: cEVR: 83–92% vs 77% Naïve G3: cEVR: 81–89% vs 59% |
Profile similar to PR | 2–3 | |||
| ABT 26752 | Abbott | II | 29 | 5–200 mg QD | NS5A.I + PR 12 w + PR 36 w | Naïve GT1: cEVR: 80–100% | Profile similar to PR | 1 |
Abbreviations: cEVR, complete early virologic response (Week 12); PR, pegylated–interferon + ribavirin; QD, once daily; RBV, ribavirin; RGT, response-guided therapy; RVR, rapid virologic response (Week 4); SVR, sustaines virologic response; SVR12, sustained virological response at week 12; wk, week.